The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ACHILLES THERAPEUTICS PLC | SPONSORED ADS | 00449L102 | 2,127,145 | 2,390,050 | SH | DFND | 2 | 0 | 2,390,050 | 0 | ||
| DYNE THERAPEUTICS INC | COM | 26818M108 | 81,543,351 | 6,131,079 | SH | DFND | 2 | 0 | 6,131,079 | 0 | ||
| ENGENE HOLDINGS INC | COM | 29286M105 | 53,384,031 | 5,783,752 | SH | DFND | 1 | 0 | 5,783,752 | 0 | ||
| ENGENE HOLDINGS INC | W EXP 10/31/2028 | 29286M113 | 2,042,611 | 3,403,072 | SH | DFND | 1 | 0 | 3,403,072 | 0 | ||
| ENGENE HOLDINGS INC | COM | 29286M105 | 26,713,457 | 2,894,199 | SH | DFND | 0 | 2,894,199 | 0 | |||
| ENGENE HOLDINGS INC | W EXP 10/31/2028 | 29286M113 | 403,815 | 475,076 | SH | DFND | 0 | 475,076 | 0 | |||
| NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | N62509109 | 58,040,102 | 5,196,070 | SH | DFND | 1 | 0 | 5,196,070 | 0 | ||
| NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | N62509109 | 74,117,317 | 6,635,391 | SH | DFND | 2 | 0 | 6,635,391 | 0 | ||
| REPLIMUNE GROUP INC | COM | 76029N106 | 41,024,165 | 4,866,499 | SH | DFND | 0 | 4,866,499 | 0 | |||